BlackRock
CGON icon

BlackRock’s CG Oncology CGON Stock Holding History

BlackRock’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445M Buy
6,256,288
+1,192,108
+24% +$77.9M 0.01% 1305
2026
Q1 		$343M Buy
5,064,180
+220,938
+5% +$12.5M 0.01% 1353
2025
Q4 		$201M Buy
4,843,242
+256,728
+6% +$10.6M ﹤0.01% 1684
2025
Q3 		$185M Buy
4,586,514
+130,091
+3% +$3.78M ﹤0.01% 1707
2025
Q2 		$116M Buy
4,456,423
+101,363
+2% +$2.44M ﹤0.01% 1948
2025
Q1 		$107M Buy
4,355,060
+293,930
+7% +$8.27M ﹤0.01% 1948
2024
Q4 		$116M Buy
4,061,130
+490,203
+14% +$16.8M ﹤0.01% 1989
2024
Q3 		$135M Buy
3,570,927
+1,594,857
+81% +$55.9M ﹤0.01% 1909
2024
Q2 		$62.4M Sell
1,976,070
-542,480
-22% -$18.8M ﹤0.01% 2288
2024
Q1 		$111M Buy
+2,518,550
New +$103M ﹤0.01% 2002

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock's CGON Position: Q2 2026 in Review

BlackRock increased its CG Oncology (CGON) stake by 24% in Q2 2026, buying an estimated $77.9M and bringing the position to 6,256,288 shares worth $445M. The position accounts for 0.01% of the portfolio, ranked #1305.

BlackRock first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 226 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • BlackRock held 6,256,288 shares of CG Oncology worth $445M as of Q2 2026.
  • BlackRock bought 1,192,108 CG Oncology shares in Q2 2026, an estimated $77.9M.
  • CG Oncology made up 0.01% of BlackRock's portfolio in Q2 2026, its #1305 holding.
  • BlackRock first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 226 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.